IN BRIEF: Hutchmed and AstraZeneca launch phase two cancer med trial

(Alliance News) - Hutchmed (China) Ltd - Hong-Kong based pharmaceutical company - Starts phase ...

Alliance News 28 July, 2021 | 10:33AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Hutchmed (China) Ltd - Hong-Kong based pharmaceutical company - Starts phase two trial of cancer treatment Orpathys, whose generic name is savolitinib. First dose administered on Tuesday. Hutchmed in partnership with AstraZeneca PLC and Beijing Cancer Hospital to conduct the trial. This follows multiple gastric cancer - cancer formed in the lining of the stomach - studies. Trial will probe the effectiveness of Orpathys in sufferers of advanced or metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction, cancer of the oesophagus which connects a body's mouth to the stomach. Metastatic cancer refers to when the disease spreads to other parts of the body.

Current stock price: 575.00 pence, up 7.1% on Wednesday

Year-to-date change: up 25%

By Josie O'Brien; josieobrien@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 11,268.00 GBX 0.16
HUTCHMED (China) Ltd 290.00 GBX 5.07 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures